CL King Downgrades Minerals Technologies to Neutral

CL King analyst David Silver downgrades Minerals Technologies (NYSE:MTX) from Buy to Neutral.

byBenzinga Newsdesk

August 30, 2022

1 minute read

CL King analyst David Silver downgrades Minerals Technologies (NYSE:MTX) from Buy to Neutral.

Paycor HCM Raised $425.5M Via IPO At $23 Per Share, Trading Begins Today

By Anusuya Lahiri

Today, 2:59 AM

Human Capital Management (HCM) software creator Paycor HCM Inc (NASDAQ:PYCR) priced 18.5 million shares at $23 per share in its initial…

PYCR

Analyst Ratings

What 10 Analyst Ratings Have To Say About DraftKings

By Benzinga Insights

Today, 2:59 AM

Over the past 3 months, 10 analysts have published their opinion on DraftKings (NASDAQ:DKNG) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

DKNG

Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration

By Vandana Singh

Today, 2:59 AM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) revealed new Phase 2 proof-of-concept trial data on Eylea (aflibercept) injection in patients with wet age-related macular…

BAYRY

Agilent Technologies Reports Its PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark Approval As Companion Diagnostic Test In Advanced, Metastatic Gastric, Gastroesophageal Junction Or Esophageal Adenocarcinoma

By Benzinga Newsdesk

Today, 2:59 AM

Agilent Technologies Inc. (NYSE:A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or

CL King Downgrades Minerals Technologies to Neutral

Related Posts

Paycor HCM Raised $425.5M Via IPO At $23 Per Share, Trading Begins Today

What 10 Analyst Ratings Have To Say About DraftKings

Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration

Agilent Technologies Reports Its PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark Approval As Companion Diagnostic Test In Advanced, Metastatic Gastric, Gastroesophageal Junction Or Esophageal Adenocarcinoma